Acquired in-process research and development
InvestingEli Lilly Acquired in-process research and development decreased by 32.7% to $441.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 64.4%, from $268.60M to $441.50M. Over 3 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 74.8% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
Detailed definition
This represents the cash outflow for the acquisition of in-process research and development projects from other entities...
Peer comparison
High in the pharmaceutical industry where external innovation is a primary driver of long-term revenue.
Metric ID:
cf_acquired_ipr_dHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $174.00M | $172.60M | $491.80M | $440.40M | $62.40M | $235.00M | $97.10M | $2.98B | $637.30M | $96.50M | $154.30M | $2.83B | $268.60M | $1.76B | $153.80M | $655.70M | $441.50M |
| QoQ Change | — | +596.0% | -0.8% | +184.9% | -10.5% | -85.8% | +276.6% | -58.7% | >999% | -78.6% | -84.9% | +59.9% | >999% | -90.5% | +554.1% | -91.2% | +326.3% | -32.7% |
| YoY Change | — | — | — | — | >999% | -64.1% | -52.2% | -78.0% | >999% | — | -58.9% | +58.9% | -5.0% | -57.9% | >999% | -0.3% | -76.8% | +64.4% |
Range$25.00M – $2.98B
CAGR+96.5%
Avg YoY Growth+598.5%
Median YoY Growth-5.0%
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Eli Lilly's acquired in-process research and development?
- Eli Lilly (LLY) reported acquired in-process research and development of $441.50M in Q4 2025.
- How has Eli Lilly's acquired in-process research and development changed year-over-year?
- Eli Lilly's acquired in-process research and development increased by 64.4% year-over-year, from $268.60M to $441.50M.
- What is the long-term trend for Eli Lilly's acquired in-process research and development?
- Over 3 years (2021 to 2025), Eli Lilly's acquired in-process research and development has grown at a 74.8% compound annual growth rate (CAGR), from $563.40M to $3.01B.
- What does acquired in-process research and development mean?
- Cash spent to acquire research projects or drug candidates currently in development.